Active substance
Prednisone
- SFDA 2
- US FDA 123
- Health Canada 5
- US price lines 11
- WHO EML 3
- Safety 5
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| PREDONE 10MG TAB | 10 mg | Tablet · Oral use | 100 Blister | SAR 16.50 | NCE · Prescription | WEST-WARD | Withdrawn by MAH · Not Marketed |
| PREDONE 20MG TAB | 20 mg | Tablet · Oral use | 100 Blister | SAR 27.10 | NCE · Prescription | WEST-WARD | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PREDNISONE | 5MG | tablet · oral | WATSON LABS | Prescription | 17 Jan 1972 |
| PREDNISONE | 5MG; 1MG; 2.5MG; 10MG; 20MG; 50MG | tablet · oral | HIKMA PHARMS | Prescription | 21 Apr 1972 |
| PREDNISONE | 20MG; 5MG; 10MG | tablet · oral | MYLAN | Prescription | 26 Feb 1974 |
| PREDNISONE | 20MG | tablet · oral | CHARTWELL MOLECULAR | Prescription | 27 Jun 1974 |
| PREDNISONE | 20MG | tablet · oral | WATSON LABS | Prescription | 11 Nov 1976 |
| PREDNISONE | 10MG | tablet · oral | WATSON LABS | Prescription | 12 Nov 1976 |
| PREDNISONE | 5MG/5ML | solution · oral | HIKMA PHARMS | Prescription | 8 Nov 1984 |
| PREDNISONE INTENSOL | 5MG/ML | solution · oral | HIKMA PHARMS | Prescription | 20 Feb 1985 |
| PREDNISONE | 20MG; 5MG; 10MG | tablet · oral | SUN PHARM INDUSTRIES | Prescription | 4 Dec 1985 |
| PREDNISONE | 10MG; 5MG; 20MG; 2.5MG; 50MG | tablet · oral | JUBILANT CADISTA | Prescription | 29 Aug 2001 |
| PREDNISONE | 5MG; 10MG | tablet · oral | PH HEALTH | Prescription | 12 Jul 2002 |
| PREDNISONE | 20MG | tablet · oral | PH HEALTH | Prescription | 12 Feb 2003 |
| PREDNISONE | 2.5MG | tablet · oral | PH HEALTH | Prescription | 21 Dec 2004 |
| PREDNISONE | 1MG | tablet · oral | PH HEALTH | Prescription | 21 Dec 2004 |
| PREDNISONE | 1MG | tablet · oral | JUBILANT CADISTA | Prescription | 6 Jun 2005 |
| PREDNISONE | 2.5MG; 5MG; 10MG; 20MG; 50MG | tablet · oral | NOVITIUM PHARMA | Prescription | 15 Nov 2019 |
| PREDNISONE | 1MG; 5MG | tablet · oral | AMNEAL | Prescription | 16 Jun 2020 |
| PREDNISONE | 10MG; 20MG | tablet · oral | AMNEAL | Prescription | 24 Jun 2020 |
| PREDNISONE | 1MG | tablet · oral | STRIDES PHARMA | Prescription | 2 Sep 2020 |
| PREDNISONE | 10MG; 20MG; 50MG; 2.5MG; 5MG | tablet · oral | STRIDES PHARMA | Prescription | 11 Feb 2021 |
| PREDNISONE | 1MG | tablet · oral | NOVITIUM PHARMA | Prescription | 6 Jul 2021 |
| PREDNISONE | 1MG | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 16 Nov 2021 |
| PREDNISONE | 2.5MG; 5MG; 10MG; 20MG; 50MG | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 28 Mar 2022 |
| PREDNISONE | 5MG; 10MG; 20MG | tablet · oral | POINTVIEW HLDINGS | Prescription | 5 Dec 2023 |
| PREDNISONE | 1MG; 2MG | tablet, delayed release · oral | DR REDDYS | Prescription | 1 Oct 2025 |
98 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO PREDNISONE TAB 50MG | 00550957 | 50 MG | TABLET · ORAL | APOTEX INC |
| APO PREDNISONE TAB 5MG | 00312770 | 5 MG | TABLET · ORAL | APOTEX INC |
| TEVA-PREDNISONE | 00021695 | 5 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-PREDNISONE | 00232378 | 50 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| WINPRED | 00271373 | 1 MG | TABLET · ORAL | AA PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | PREDNISONE 1 MG TABLET | $0.03864 | per EA | 23 Sep 2026 |
| US NADAC | PREDNISONE 10 MG TAB DOSE PACK | $0.58481 | per EA | 23 Sep 2026 |
| US NADAC | PREDNISONE 10 MG TABLET | $0.05328 | per EA | 23 Sep 2026 |
| US NADAC | PREDNISONE 2.5 MG TABLET | $0.06607 | per EA | 23 Sep 2026 |
| US NADAC | PREDNISONE 20 MG TABLET | $0.06431 | per EA | 23 Sep 2026 |
| US NADAC | PREDNISONE 5 MG TAB DOSE PACK | $0.33674 | per EA | 23 Sep 2026 |
| US NADAC | PREDNISONE 5 MG TABLET | $0.03669 | per EA | 23 Sep 2026 |
| US NADAC | PREDNISONE 5 MG/5 ML SOLUTION | $0.4331 | per ML | 23 Sep 2026 |
| US NADAC | PREDNISONE 5 MG/5 ML SOLUTION | $0.60543 | per ML | 23 Sep 2026 |
| US NADAC | PREDNISONE 50 MG TABLET | $0.17117 | per EA | 23 Sep 2026 |
| US NADAC | PREDNISONE INTENSOL 5 MG/ML | $3.21489 | per ML | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 8.2.4. Hormones and antihormones · complementary
Therapeutic equivalent to prednisolone for Lymphoid leukaemia, not elsewhere classified; Therapeutic equivalent to prednisolone for Diffuse large B-cell lymphoma, not otherwise specified; Therapeutic equivalent to prednisolone for Chronic lymphocytic leukaemia or small lymphocytic lymphoma; Therapeutic equivalent to prednisolone for Plasma cell myeloma; Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-negative; Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-positive; Therapeutic equivalent to prednisolone for Langerhans cell histiocytosis; Therapeutic equivalent to prednisolone for Hodgkin lymphoma; Therapeutic equivalent to prednisolone for Malignant neoplasms of prostate; Therapeutic equivalent to prednisolone for Follicular lymphoma - 3. Antiallergics and medicines used in anaphylaxis · core
Therapeutic equivalent to prednisolone for Allergic or hypersensitivity conditions of unspecified type - 18.1. Adrenal hormones and synthetic substitutes · core
Therapeutic equivalent to prednisolone for Adrenocortical insufficiency
Safety signals and safety-related labeling changes
- US FDA 5 Jun 2024 RAYOS — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 11 Feb 2021 PRAC signal: Bradycardia
Action for MAH: update of the product information: Yes - EMA PRAC 1 Oct 2020 PRAC signal: Bradycardia
Action for MAH: update of the product information: No - EMA PRAC 6 Jul 2017 PRAC signal: Induced scleroderma renal crisis
Action for MAH: update of the product information: Yes - EMA PRAC 9 Jun 2017 PRAC signal: Induced scleroderma renal crisis
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.